A Phase 1 Study To Evaluate The Safety, Pharmacokinetics, And Pharmacodynamics Of PF 04449913, An Oral Hedgehog Inhibitor, Administered As Single Agent In Select Hematologic Malignancies
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
First cycle dose limiting toxicities (Phase 1a)
12 months
Yes
Pfizer CT.gov Call Center
Study Director
Pfizer
United States: Food and Drug Administration
B1371001
NCT00953758
March 2010
February 2013
Name | Location |
---|---|
Pfizer Investigational Site | Blendora, California 91740 |
Pfizer Investigational Site | Houston, Texas 77030 |
Pfizer Investigational Site | Federal Way, Washington 98003 |